Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
20 hedge funds and large institutions have $20.7M invested in Oncternal Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
167% more capital invested
Capital invested by funds: $7.74M → $20.7M (+$12.9M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
6.4% more ownership
Funds ownership: 9.12% → 15.52% (+6.4%)
5% more funds holding
Funds holding: 19 → 20 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$3.63M |
| 2 |
A
Abingworth
London,
United Kingdom
|
+$2.18M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$459K |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$404K |
| 5 |
JP Morgan Chase
New York
|
+$26.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLI
Kelman-Lazarov Inc
Memphis,
Tennessee
|
-$88K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$13K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.5K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$1.08K |
| 5 |
Morgan Stanley
New York
|
-$900 |
ONCT Hedge Fund Activity: Q3 2017 in Review
20 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2017, worth a combined $20.7M — up 167% from $7.74M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ONCT positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $3.63M. The largest seller was Kelman-Lazarov Inc, exiting entirely with an estimated $88K sold.
- 20 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2017, up from 19 in Q2 2017.
- Funds reported $20.7M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2017, up 167% quarter-over-quarter.
- 5 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2017 and 4 closed out, a net change of +1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2017 was Boxer Capital, an estimated $3.63M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2017 was Kelman-Lazarov Inc, an estimated $88K sold.
Based on aggregated 13F filings for Q3 2017.